The economic value of improvements in health status for patients with type 2 diabetes seems to exceed or equal increases in health care spending, suggesting that those increases were worth the extra c
Background: The net economic value of increased health care spending remains unclear, especially for chronic diseases.
If Congress creates a public option in health-care insurance, will that inevitably lead to a single-payer system, with the government everyone's insurer?
A broad consensus holds that increased medical capability—technology—is the primary driver of health spending growth.
Dartmouth researchers have demonstrated that there is tremendous geographic variation in the efficiency of health care delivery systems, fostered by perverse incentives that penalize integration, rewa
Pharmaceutical expenditures have grown rapidly in recent decades, and now total nearly 10% of health care costs.
Spending on health care in markets with a larger percentage of primary care physicians (PCPs) is lower at any point in time than is true in other markets.
The article reviews the book "Medical Research for Hire: The Political Economy of Pharmaceutical Clinical Trials," by Jill A. Fisher.
Book abstract: Pharmaceutical policies are interlinked globally and at the same time deeply rooted in local culture.
Propensity score matching estimators (Rosenbaum and Rubin, 1983) are widely used in evaluation research to estimate average treatment effects.
Get smart & reliable public policy insights right in your inbox.